# A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome

> **NCT06304103** · PHASE2 · RECRUITING · sponsor: **Kind Pharmaceuticals LLC** · enrollment: 63 (estimated)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** AND017

## Key facts

- **NCT ID:** NCT06304103
- **Lead sponsor:** Kind Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-14
- **Primary completion:** 2026-12
- **Final completion:** 2027-05
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06304103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06304103, "A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06304103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*